Supplementary Figure S1. Promotional material to advertise ETHOS Engage study prior to recruitment.

UNSW SYDNEY

Kirby Institute

ETHOS ENGAGE

Get your liver scan and Hep C testing!

You can participate in this study if you have a history of injecting drugs and are:

- ***Over 18***
- ***Currently on OST (methadone or buprenorphine) or have recently injected drugs (last 6 months)****

You will receive a $30 gift voucher in return for taking part.

Join the study here: **Address**.

Wednesday 19th May: 9am-11am, Thursday 20th & Friday 21st May: 9am-3pm.

Please call (Number) for further details.

Your participation in this study is confidential.

The ethical aspects of this research project have been approved by the HREC of St Vincent's Hospital (reference number: HREC/17/SVH/113)

Version 3.0, 11 October 2019

Supplementary Figure S2. ETHOS Engage participant flowchart, current HCV status and treatment uptake at 24 months post-enrolment (N = 1388).

Supplementary Table S1. Characteristics of study population according to current HCV infection (N=1374).

Characteristic		All	No current HCV infection	Current HCV infection
		N (col%)	n (col%)	n (col%)
Total (N)		1374 (100%)	1057 (100%)	317 (100%)
Age at enrolment	Median (IQR)	43 (37-50)	43 (37-50)	43 (37-49)
Gender	Male	880 (64%)	675 (64%)	205 (65%)
	Female	491 (36%)	381 (36%)	110 (35%)
	Other	3 (0%)	1 (0%)	2 (1%)
Aboriginal or Torres Strait Islander	No	1052 (77%)	811 (77%)	241 (76%)
	Yes	322 (23%)	246 (23%)	76 (24%)
Homeless	No	1227 (89%)	959 (91%)	268 (85%)
	Yes	147 (11%)	98 (9%)	49 (15%)
Currently receiving OAT	No	387 (28%)	289 (27%)	98 (31%)
	Yes	987 (72%)	768 (73%)	219 (69%)
Incarceration history	Never	451 (33%)	378 (36%)	73 (23%)
	More than 12 months ago	678 (53%)	506 (48%)	172 (61%)
	In last 12 months	245 (14%)	173 (16%)	72 (16%)
Recency of injecting	More than a month ago	506 (37%)	410 (39%)	96 (30%)
	Within last month	868 (63%)	647 (61%)	221 (70%)
Hazardous alcohol consumption†	No	871 (63%)	683 (65%)	188 (59%)
	Yes	500 (36%)	373 (35%)	127 (40%)
Fibrosis - Fibroscan result (kpa)	<7.0	966 (70%)	782 (74%)	184 (58%)
	>7.0	320 (23%)	205 (19%)	115 (36%)
	Unknown	88 (6%)	70 (7%)	18 (6%)

† Excluding people who did not identify as men or women (n=2)
Acronyms – OAT: opioid agonist treatment, HCV: hepatitis C virus

Supplementary Table S2. Cumulative probability of treatment initiation by 12 months and 24 months following HCV diagnosis.

		Follow up time, years (95% CI)	
		1	2
Overall		38% (33%-44%)	62% (55%-69%)
Age at enrolment	<45	35% (29%-43%)	58% (49%-68%)
	≥45	42% (34%-51%)	67% (57%-77%)
Gender	Male	38% (32%-45%)	58% (50%-67%)
	Female	37% (29%-47%)	69% (57%-80%)
	Other	-	-
Aboriginal or Torres Strait Islander	No	41% (35%-47%)	66% (58%-74%)
	Yes	30% (21%-42%)	50% (36%-66%)
Homeless	No	42% (37%-48%)	66% (58%-73%)
	Yes	16% (9%-30%)	42% (25%-65%)
Currently receiving OAT	No	31% (23%-41%)	58% (44%-73%)
	Yes	42% (35%-48%)	64% (56%-72%)
Incarceration history	Never	45% (35%-57%)	78% (65%-89%)
	More than 12 months ago	40% (33%-47%)	64% (54%-73%)
	In last 12 months	28% (19%-40%)	39% (26%-55%)
Recency of injecting	More than a month ago	41% (32%-51%)	67% (57%-78%)
	Within last month	37% (31%-44%)	59% (49%-68%)
Hazardous alcohol consumption†	No	38% (32%-46%)	59% (50%-68%)
	Yes	37% (29%-46%)	67% (55%-78%)
Fibrosis -Fibroscan result (kpa)	<7.0	45% (38%-54%)	63% (54%-73%)
	>7.0	31% (24%-40%)	61% (50%-72%)
	Unknown	28% (13%-54%)	64% (36%-90%)

† Excluding people who did not identify as men or women (n=2)
Acronyms – OAT: opioid agonist treatment, HCV: hepatitis C virus, CI: confidence interval